Integrated Core Strategies Files Schedule 13G/A for Karyopharm Therapeutics
A Schedule 13G/A for Karyopharm Therapeutics was filed by Integrated Core Strategies (US) LLC.
Related stories
Amazon Shares Fall 7% After Q3 Results Show Weaker Free Cash Flow
Amazon shares fell more than 7% in extended trading after third-quarter results missed expectations, fourth-quarter revenue guidance midpoint trailed projections and free cash flow
M impact | EQUITY | Oct 30, 2026, 12:51 AM UTC
Japan's Nikkei average falls 2%
M impact | EQUITY | Oct 30, 2026, 12:50 AM UTC
KPa-BM Shares Halt Trading in Hong Kong Pending Takeover Code Announcement
M impact | EQUITY | Oct 30, 2026, 12:49 AM UTC
U.S. Pledges Tariff Relief to Secure Audi’s U.S. Factory Project
The Trump administration has pledged tariff relief to Volkswagen’s Audi to secure its U.S. factory project, Reuters reported, citing two people familiar with the matter.
M impact | EQUITY | Oct 30, 2026, 12:49 AM UTC
Buenaventura Announces Third-Quarter and Nine-Month 2026 Results
M impact | EQUITY | Oct 30, 2026, 12:45 AM UTC
APR Q3 Operating Profit Rises 68.9% Year Over Year
APR reported third-quarter 2026 consolidated operating profit, up 68.9% year over year.
M impact | EQUITY | Oct 30, 2026, 12:44 AM UTC